Co-treatment of suberoylanilide hydroxamic acid and mitomycin-C induces the apoptosis of Rabbit Tenon's capsule fibroblast and improves the outcome of glaucoma filtration surgery

Current Eye Research

Volumn 33, Issue 3, 2008, Pages 237-245

  Kim, Tae Hyun ^a   Kim, Sang Woo ^a   Woo, Jung Min ^a   Rho, Jee Hyun ^a   Lee, Dong Jun ^a   Park, Jung Min ^a   Jeong, Woo Jin ^a   Park, Woo Chan ^a   Yoo, Young Hyun ^a   Rho, Sae Heun ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

Apoptosis; Deacetylase inhibitor; Glaucoma filtration surgery; Histone SAHA; Mitomycin C

Indexed keywords

ALKYLATING AGENT; CASPASE 3; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; MITOMYCIN; PROTEIN BAD; PROTEIN P53; VORINOSTAT;

ANIMAL; APOPTOSIS; ARTICLE; CONNECTIVE TISSUE CELL; CULTURE TECHNIQUE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; FIBROBLAST; FIBROSIS; FILTERING OPERATION; FLUORESCENT ANTIBODY TECHNIQUE; GLAUCOMA; INTRAOCULAR PRESSURE; METABOLISM; NICK END LABELING; PATHOLOGY; PHOSPHORYLATION; PLASTIC SURGERY; RABBIT; UPREGULATION; WESTERN BLOTTING;

ALKYLATING AGENTS; ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BLOTTING, WESTERN; CASPASE 3; CELL CULTURE TECHNIQUES; CONNECTIVE TISSUE CELLS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FIBROBLASTS; FIBROSIS; FILTERING SURGERY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLAUCOMA; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; IN SITU NICK-END LABELING; INTRAOCULAR PRESSURE; MITOMYCIN; PHOSPHORYLATION; RABBITS; SURGICAL FLAPS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 44049099673     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680701875281     Document Type: Article

References (44)

1. Teng CC, Chi HH, Katzin HM. Histology and mechanism of filtering operations. Am J Ophthalmol. 1959;47: 16-33.
2. Halger M, Chevez-Barrios P, Lieberman MW, et al. Decorin and suramine inhibit ocular fibroblast collagen production. Graefe's Arch Clin Exp Ophthalmol. 1997;235: 399-403.
3. Tilleul P, Denis P, Maignen F, et al. Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) in glaucoma surgery rabbits. Ophthalmol Res. 1997;29: 218-226.
4. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101: 795-798.
5. Herschler J, Claflin AJ, Fiorentino G. The effect of aqueous humor on the growth of subconjunctival fibroblasts in tissue culture and its implications for glaucoma surgery. Am J Ophthalmol. 1980;89:245- 249.
6. Tahery MM, Lee DA. Pharmacologic control of wound healing in glaucoma filtration surgery. J Ocul Pharmacol. 1989;5: 155-179.
7. Esson DW, Neelakantam A, Iyer SA, et al. Expression of connective tissue growth factor after glaucoma filtration surgery in a rabbit model. Invest Ophthalmol Vis Sci. 2004;45: 485-491.
8. Chen CW. Enhanced intraocular pressure controlling effectiveness of trabeculectomy results by local application of mitomycin C. Trans Asia Pac Acad Ophthalmol. 1983;9: 172-177.
9. Matsuda T, Tanihara H, Hangai M, et al. Surgical results and complications of trabeculectomy with intraoperative application of mitomycin C. Jpn J Ophthalmol. 1996;40: 526-532.
10. Singh J, O'Brien C, Chawla HB. Success rate and complications of intraoperative 0.2 mg/ml mitomycin C in trabeculectomy surgery. Eye. 1995;9: 460-466.
11. Derick RJ, Pasquale L, Quigley HA, Jampel H. Potential toxicity of mitomycin C. Arch Ophthalmol. 1991;109:1635.
12. Schraermeyer U, Diestelhorst M, Bieker A, et al. Morphologic proof of the toxicity of mitomycin C on the ciliary body in relation to different application methods. Graefes Arch Clin Exp Ophthalmol. 1999;237: 539-600.
13. Sherwood MB. A sequential, multiple-treatment, targeted approach to reduce wound healing and failure of glaucoma filtration surgery in a rabbit model (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104: 478-492.
14. Franks WA, Hitchings RA. Complication of 5-fluorouracil after trabeculectomy. Eye. 1991;5: 385-389.
15. Weinreb RN. Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects. Opthalmology. 1987;94: 564-570.
16. Iizuka M, Smith MM. Functional consequences of histone modifications. Curr Opin Genet Dev. 2003;13: 154-160.
17. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001;7: 437-443.
18. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92: 1210-1216.
19. Dokmanovic M, Marks PA. Prospects: Histone deacetylase inhibitors. J Cell Biochem. 2005;96: 293-304.
20. Cohen LA, Amin S, Marks PA, et al. Chemoprevention of carcinogen induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. 1999;19: 4999-5005.
21. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000;184: 1-16.
22. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001;13: 477-483.
23. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell. 2003;4:13- 18.
24. Sakamoto T, Oshima Y, Sakamoto M, et al. Electroporation and bleomycin in glaucoma filtering surgery. Invest Ophthalmol Vis Sci. 1997;38: 2864-2868.
25. Avila M, Ortiz G, Lozano JM, et al. Effects of RGD (Arg-Gly-Asp) peptides on glaucoma filtration surgery in rabbits. Ophthalmic Surg Laser. 1998;29: 309-317.
26. Jampel H, Moon J. The effect of paclitaxel powder on glaucoma filtration surgery in rabbits. J Glaucoma. 1998;7: 170-177.
27. Gillies MC, Goldberg I, Young S. Glaucoma filtering surgery interferon alpha 2b. J Glaucoma. 1993;2: 229-235.
28. Al-Aswad LA, Huanng M, Netland PA. Inhibition of Tenon's fibroblast proliferation and enhancement of filtration surgery in rabbits with cytosine arabiniside. J Ocul Pharm Ther. 1999;15: 41-49.
29. Hueber A, Welsandt G, Jordan JF, et al. Chracterization of CD95 ligand (CD95L)-induced apoptosis in human Tenon fibroblast. Exp Eye Res. 2002;75: 1-8.
30. Cristofanilli M, Pescosolido N, Risuleo G, Scarsella G. A murine cell culture model for post-trabeculectomy antifibrotic treatment: Induction of apoptosis by cyclosporin. Acta Ophthalmol Scand. 2001;79: 309-312.
31. Constable PH, Crowston JG, Occleston NL, Khaw PT. The effects of single doses of β radiation on the wound healing behaviour of human Tenon's capsule fibroblasts. Br J Ophthalmol. 2004;88:169- 173.
32. Siriwardena D, Khaw PT, King AJ, et al. Human antitransforming growth factor β2 monoclonal antibody - A new modulator of wound healing in trabeculectomy. Ophthalmology. 2002;109:427- 431.
33. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinase. J Biol Chem. 1987;262:5592- 5595.
34. Yu C, Rahmani M, Conrad D, et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood. 2003;102: 3765-3774.
35. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Retv Drug Discov. 2006;5: 769-784.
36. Mitsiades CS, Poulaki V, McMullan C, et al. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res. 2005;11: 3958-3965.
37. Sonnemann J, Hartwig M, Plath A, et al. Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett. 2006;232:148- 160.
38. Mei S, Ho AD, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer. Int J Oncol. 2004;25:1509- 1519.
39. Roh MS, Kim CW, Park BS, et al. Trichostatin A induces apoptosis on human osteosarcoma cells in histone acetylation- and mitochondriadependent fashions. Apoptosis. 2004;9: 583-589.
40. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol. 2003;66: 1537-1545.
41. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26: 1351-1356.
42. Skuta GL, Parish RK. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;32: 149-170.
43. Miller MH, Grierson I, Unger WI, Hitchings RA. Wound healing in an animal model of glaucoma fistulizing surgery in the rabbit. Ophthalmic Surg. 1989;20: 350-357.
44. Miller MH, Joseph NH, Ennis KW, et al. An animal model of filtration surgery. Trans Ophthalmol Soc UK. 1985;104: 893-897.